Avid Bioservices Inc (CDMO)

[JamesGMS]

North,re your post below:

“...depends on the company.” were the words Dr Jedd Wolchok said as he exited the auditorium at JHU earlier in December 2017.

1) Has JW presented the MSKCC clinical trial design to a) the new BOD of PPHM, and/or b) any other “company”?

2) What indication(s) was that clinical trial design for? IMO, more than one possible trial design exists by virtue of data content of a multiplicity of posters/abstracts presented at SITC 2016, AACR 2017 and SITC 2017.

3) When will we SHs find out about answers to the above questions, and the PPHM BOD’s reaction to issues raised by the above questions?

Perhaps your question in #1 above should be amended ever so slightly to read as follows: any other “companies”?

North, many balls are in play as your post suggests - and we would agree with you. Just as an aside - remember a core tenet of Tappan's investment philosophy - they have "to love their investment" before stepping up - and then, after learning even more, they more than doubled their initial position - and no doubt continue to add to it.

Re Golfho's proposed letter - I think you would likely agree that there is now no need for it - as the value of the IP is NOW clearly known by our new BOD - but more importantly by those who are now actively marketing it to multiple suitors. And of course Dr. Wolchok has and will continue to play an integral role in the process - as your posts have suggested for some time now - Jedd knows what he has - and he wants all of it to be developed as rapidly as possible.

As for SK and JS - they will shortly either be joining an acquiring company or - and we think more likely - becoming high paid consultants for multiple entities.

We shall see soon enough : )

James